Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1Natalia Stella-Ascariz, Clotilde Allavena, Christian Hoffmann et al.|The Journal of Infectious Diseases|2018Cited by 33
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 27
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Luminita Schneider, Lambert Assoumou et al.|Clinical Infectious Diseases|2022Cited by 17
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 2